Glaxosmithkline Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 15 Feb 2025
Result Summary
- Glaxosmithkline Pharmaceuticals Ltd reported a 5.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 18.1%.
- Its expenses for the quarter were down by 4.2% QoQ and up 11.9% YoY.
- The net profit decreased 9.0% QoQ and increased 402.8% YoY.
- The earnings per share (EPS) of Glaxosmithkline Pharmaceuticals Ltd stood at 13.6 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 984.49 | 1045.31 | 833.37 | -5.8% | 18.1% |
Total Expenses | 676.39 | 706.19 | 604.63 | -4.2% | 11.9% |
Profit Before Tax | 308.10 | 343.81 | 65.43 | -10.4% | 370.9% |
Tax | 78.22 | 91.31 | 19.71 | -14.3% | 296.9% |
Profit After Tax | 229.88 | 252.50 | 45.72 | -9.0% | 402.8% |
Earnings Per Share | 13.60 | 14.90 | 2.70 | -8.7% | 403.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Glaxosmithkline Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacture, and marketing of prescription medicines and vaccines. The company operates in a highly competitive sector that is driven by innovation and regulatory compliance. Glaxosmithkline Pharmaceuticals has a portfolio that includes products across various therapeutic areas such as respiratory, oncology, and anti-infectives. The company is known for its commitment to research and development, aiming to address unmet medical needs. Recent developments in the industry have seen an increased focus on digital health and personalized medicine, although specific recent major developments for Glaxosmithkline Pharmaceuticals are not provided in the available data.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Glaxosmithkline Pharmaceuticals Ltd reported a total income of ₹984.49 crores. This represents a decrease of 5.8% compared to the previous quarter (Q2FY25), where the total income was ₹1045.31 crores. However, on a year-over-year basis, the company experienced an 18.1% increase in total income compared to Q3FY24, where the total income was ₹833.37 crores. This reflects a notable improvement over the same period last year, indicating significant growth in revenue generation.
Profitability
For Q3FY25, Glaxosmithkline Pharmaceuticals Ltd recorded a profit before tax of ₹308.10 crores, which is a 10.4% decline from the previous quarter's figure of ₹343.81 crores. Despite this quarter-over-quarter decrease, the profit before tax surged by 370.9% year-over-year from ₹65.43 crores in Q3FY24. The company's profit after tax for Q3FY25 was ₹229.88 crores, down 9.0% from ₹252.50 crores in Q2FY25, but up 402.8% from ₹45.72 crores in Q3FY24. This significant year-over-year growth in profitability metrics highlights a substantial enhancement in the company's financial performance compared to the previous year.
Operating Metrics
The total expenses for Glaxosmithkline Pharmaceuticals Ltd in Q3FY25 amounted to ₹676.39 crores, marking a 4.2% reduction from the previous quarter's expenses of ₹706.19 crores. In comparison to the same quarter last year, total expenses increased by 11.9% from ₹604.63 crores in Q3FY24. Earnings per share (EPS) for Q3FY25 was ₹13.60, reflecting an 8.7% decrease from the previous quarter's EPS of ₹14.90. However, the EPS rose dramatically by 403.7% on a year-over-year basis from ₹2.70 in Q3FY24. These changes in key operating metrics indicate fluctuations in cost management and shareholder value on a quarterly basis, while showcasing significant growth over the past year.
